Enjoy complimentary customisation on priority with our Enterprise License!
The global transfection technologies market size is estimated to grow by USD 675.9 million, at a CAGR of 9.66% between 2023 and 2028.
The revolutionary CRISPR/Cas9 technology enables precise genome editing by inducing targeted double-strand breaks (DSBs) at specific DNA sequences. To harness CRISPR effectively, researchers rely on efficient gene delivery systems to introduce CRISPR components into target cells. Transfection technologies like lipid-based reagents, electroporation, and viral vectors play a pivotal role in delivering CRISPR components across diverse cell types and applications. Lipid-based reagents are preferred for versatility, while electroporation excels with hard-to-transfect cells. Viral vectors offer efficient gene delivery for in vivo and ex vivo applications. CRISPR/Cas9's versatility extends to gene knockout, knock-in, activation, and repression, with promising therapeutic potential for genetic disorders and cancer. Clinical translation of CRISPR therapies underscores the importance of safe and efficient transfection technologies for gene editing applications. This growing adoption of CRISPR/Cas9 drives innovation in transfection technologies, fueling the global market's growth in research, biotechnology, and therapeutics.
To learn more about this report, Request Free Sample
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Altogen Biosystems - The company offers transfection technologies such as AltoFect Transfection Reagent, which is designed for hard to transfect cell lines and primary cell types.
Bio Rad Laboratories Inc., Danaher Corp., F. Hoffmann La Roche Ltd., GENLANTIS, ibidi GmbH, Inovio Pharmaceuticals Inc., Kytopen Corp., Life Technologies India Pvt Ltd., Lonza Group Ltd., MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OZ Biosciences, Promega Corp., QIAGEN NV, RJH BIOSCIENCES, Sartorius AG, SignaGen Laboratories, STEMCELL Technologies Inc., Takara Holdings Inc., and Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the viral-vector-based transfection segment will be significant during the forecast period. The market encompasses various techniques for delivering nucleic acids, including cell-based microarrays, physical transfection, and biochemical and viral vector transfection, into target cells for applications in biomedical research, cell therapy, and gene therapy. These technologies hold significant importance in the fields of cancer, cystic fibrosis, heart disease, and other genetic disorders, as they enable the efficient production of therapeutic proteins and the delivery of nucleic acids for gene therapy. The incidence of chronic diseases, such as cancer and obesity, has fueled the demand for advanced transfection technologies.
Get a glance at the market contribution of various segments Download PDF Sample
The viral-vector based transfection segment was the largest and was valued at USD 325.40 million in 2018. RNA interference (RNAi) and miRNA are emerging transfection technologies that offer precise control over gene expression. These technologies have the potential to revolutionize the field of personalized medicine by enabling the targeted delivery of therapeutic nucleic acids to specific cells or tissues. The market is also witnessing significant investments and fundings in the development of drug delivery systems and nucleic acid-based therapeutics. The use of HEK293 cell line and selection techniques, such as reporter gene systems and biomarkers, facilitates the optimization of transfection efficiency and specificity. In conclusion, the market is a dynamic and rapidly evolving field, driven by the increasing demand for advanced therapeutic delivery systems and the potential of gene therapy to address a wide range of diseases. The development of safe, effective, and precise transfection technologies will continue to be a key focus area for technology providers, regulatory authorities, and researchers in the years to come.
Transfection technologies play a pivotal role in the pharmaceutical and biotechnology industry, particularly in the context of genetic and proteomic biomarkers for cancer diagnostics. These technologies facilitate the efficient delivery of plasmid DNA, enabling the creation of cell-based assays, disease models, and preclinical screening platforms. The significance of transfection technologies is underscored by their ability to deliver high quantities of target molecules in a short timeframe. This expedites the drug discovery and development process, making it a vital component in the biomedical research landscape. The increasing prevalence of chronic diseases and the subsequent demand for novel therapeutics further underscore the importance of transfection technologies in this sector.
For more insights about the market share of various regions Download PDF Sample
North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers will shape the market trends during the forecast period.
The market encompasses the development, production, and application of technologies used for introducing nucleic acids, such as DNA, RNA, and oligonucleotides, into cells for various therapeutic and research purposes. This market holds significant importance in the realm of biomedical research, particularly in the areas of Cell-based therapies for Cancer, Cystic fibrosis, Heart disease, and Genetic disorders. Transfection technologies are crucial for Cell and gene therapies, enabling the delivery of therapeutic genes or RNA interferences (RNAi) like miRNA into target cells. Transfection technology plays a pivotal role in therapeutic delivery systems, drug delivery, and nucleic acid-based therapeutics. Reporter gene systems and selection techniques are essential components of these technologies, facilitating the monitoring and identification of transfected cells. Biomarkers derived from these applications contribute to the advancement of personalized medicine and disease diagnostics. Key players in this market focus on improving transfection efficiency and reducing potential side effects, ensuring the success of therapeutic interventions. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
Rising demand for monoclonal antibodies is notably driving market growth. The market plays a pivotal role in the advancement of cell-based therapies and gene therapies for various medical conditions. These technologies are instrumental in the production of monoclonal antibodies for cancer, cystic fibrosis, heart disease, and genetic disorders, among others. With the increasing incidence of chronic diseases and cancer, there is a significant demand for therapeutic delivery systems and protein production. Transfection technologies facilitate gene transfection, enabling the introduction of DNA, RNA, or oligonucleotides into cells for therapeutic purposes. Key technology providers in this field collaborate with regulatory authorities to ensure safety and efficacy. Physical and biochemical transfection methods, including viral vector transfection, are employed to deliver nucleic acids into cells. Cell-based microarrays are utilized for high-throughput screening and selection techniques in biomedical research.
Moreover, RNA interference (RNAi), miRNA, and reporter gene systems are essential components of transfection technology. Transfection technologies have significant applications in drug delivery, particularly in the context of personalized medicine. Cytotoxicity assessment is crucial to ensure the safety of these therapeutic delivery systems. Key areas of focus include the development of transfection technologies for obesity, HIV, and epigenetic biomarkers. Investments and funding continue to fuel the growth of the market, driving innovation and advancements in this field. Thus, such factors are driving the growth of the market during the forecast period.
Increased use of dual-reporter assays and co-transfection experiments is the key trend in the market. The market has experienced significant growth in recent years, driven by the increasing demand for cell-based therapies and gene therapies in the biomedical research sector. These advanced technologies are utilized in the treatment and diagnosis of various chronic diseases, including cancer, cystic fibrosis, heart disease, and genetic disorders. Transfection is a crucial process in cell therapy and gene therapy, enabling the introduction of nucleic acids, such as DNA, RNA, and oligonucleotides, into cells for protein production and therapeutic delivery. The incidence of cancer and other chronic diseases has fueled investments and fundings in transfection technology research and development. Key technology providers include Promega Corp, offering the Nano-Glo Dual-Luciferase Reporter (NanoDLR) Assay System for detecting firefly luciferase and NanoLuc luciferase activities in a single sample. Regulatory authorities and collaborative networks play a vital role in ensuring the safety and efficacy of these technologies.
Further, physical transfection methods, such as electroporation and microinjection, and biochemical transfection methods, such as lipofection and viral vector transfection, are commonly used for gene delivery. Cell-based microarrays and selection techniques facilitate the identification of effective transfection methods and the optimization of gene expression. Reporter gene systems, such as the NanoDLR Assay System, enable the determination of cytotoxicity and the evaluation of biomarkers, including epigenetic biomarkers and HIV. RNA interference (RNAi) and miRNA are essential components of gene transfection technologies, providing targeted gene silencing and regulation. Transfection technology plays a pivotal role in personalized medicine, enabling the development of therapeutic delivery systems and drug delivery vehicles tailored to individual patients. The ongoing advancements in transfection technology are expected to revolutionize the fields of biomedical research, therapeutic delivery, and nucleic acid-based therapeutics. Thus, such trends will shape the growth of the market during the forecast period.
Issues associated with efficiency of transfection is the major challenge that affects the growth of the market. The market plays a pivotal role in the advancement of cell-based therapies for various diseases, including cancer, Cystic fibrosis, and heart disease. These technologies enable the introduction of genetic material into cells, facilitating gene therapy and protein production for personalized medicine. The incidence of chronic diseases and the growing demand for therapeutic delivery systems have fueled investments and funding in this sector. Transfection technologies are utilized in biomedical research to understand the mechanisms of genetic disorders and to develop new drugs and treatments. These technologies employ physical and biochemical methods, such as viral vector transfection and electroporation, to deliver nucleic acids, including DNA, RNA, and oligonucleotides, into cells. The HEK293 cell line, a commonly used line for transfection, is essential for the production of various therapeutic proteins and RNA interference (RNAi) agents. RNAi and miRNA are crucial components of gene transfection technologies, providing selective gene silencing and regulation.
Moreover, reporter gene systems and selection techniques are employed to monitor and assess the efficiency of transfection. Biomarkers, such as epigenetic biomarkers and HIV, are also utilized to evaluate the impact of transfection on cellular processes. Technology providers and regulatory authorities collaborate to ensure the safety and efficacy of transfection technologies. Cytotoxicity and contamination, including protein, RNA, chemical, and microbial contamination, are critical concerns that must be addressed to maintain the integrity of the transfection process. Transfection technologies have significant applications in drug delivery and nucleic acid-based therapeutics, offering potential solutions for obesity and other health conditions. The market for transfection technologies is expected to grow as these technologies continue to advance and contribute to the development of innovative therapeutic approaches. Hence, the above factors will impede the growth of the market during the forecast period
The market forecast report includes the adoption lifecycle of the market growth and forecasting, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market forecasting and growth strategies.
Customer Landscape
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
The market encompasses various methods used to introduce foreign genetic material into cells for therapeutic or research purposes. Technologies such as electroporation, viral vectors, and chemical transfection are commonly employed in this field. These techniques facilitate the delivery of DNA, RNA, or other molecules into cells, enabling gene therapy, gene editing, and vaccine production. The market is driven by the increasing demand for gene therapies and personalized medicines. The ability to modify cells at a genetic level holds immense potential for treating various diseases, including genetic disorders and cancer. Furthermore, advancements in viral vector production and gene editing tools continue to fuel market growth. Transfection Technologies are also crucial in the research sector, where they are used to study gene function and gene regulation. The development of more efficient and cost-effective methods for transfection is a significant focus for researchers and industry players alike. In conclusion, the market is a dynamic and evolving field, driven by the growing demand for gene therapies and personalized medicines, as well as advancements in research and technology. The market is expected to continue growing, offering significant opportunities for companies and researchers in the life sciences industry.
Further, the market is pivotal in advancing cell based therapies and gene therapies, particularly for treating genetic and rare diseases. It addresses challenges such as hard to transfect cells through innovative Transfection technologies product providers offered by specialized product providers. Instrument and reagent suppliers play a crucial role in supporting these advancements, facilitating the delivery of genetic material such as Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) into cells. Applications extend to developing cell-based microarrays and enhancing nasal and pulmonary medication delivery methods. The market's focus on genetic biomarkers underscores its commitment to precision medicine and personalized treatment approaches, driving forward breakthroughs in biotechnology and healthcare. As research continues to evolve, the transfection technologies sector remains at the forefront of pioneering therapies that hold promise for improving patient outcomes worldwide.
Market Scope |
|
Report Coverage |
Details |
Page number |
172 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.66% |
Market growth 2024-2028 |
USD 675.9 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.45 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 46% |
Key countries |
US, China, UK, Germany, and France |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Altogen Biosystems, Bio Rad Laboratories Inc., Danaher Corp., F. Hoffmann La Roche Ltd., GENLANTIS, ibidi GmbH, Inovio Pharmaceuticals Inc., Kytopen Corp., Life Technologies India Pvt Ltd., Lonza Group Ltd., MaxCyte Inc., Merck KGaA, Mirus Bio LLC, OZ Biosciences, Promega Corp., QIAGEN NV, RJH BIOSCIENCES, Sartorius AG, SignaGen Laboratories, STEMCELL Technologies Inc., Takara Holdings Inc., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.